Metsera Inc
MTSR31.140USD
+0.840+2.77%
Cierre 08/15, 16:00（ET）Cotizaciones retrasadas 15 min
3.27BCap. mercado
PérdidaP/E TTM
Más Datos de Metsera Inc Compañía
Metsera, Inc. is a clinical-stage biotechnology company developing injectable and oral nutrient stimulated hormone (NuSH) analog peptides to treat obesity, overweight and related conditions. The Company uses its proprietary MINT peptide library of NuSH analog peptides alongside its Half-life Augmentation by Lipid Optimization, or HALO, half-life extending platform and its MOMENTUM oral NuSH analog peptide delivery platform to deliver highly differentiated product candidates. Its product pipeline includes MET-097i, MET-233i / MET-233i + MET-097i and MET-224o. MET-097i, its advanced product candidate, is a fully biased, monthly, subcutaneously injectable ultra-long acting GLP-1 RA. MET-233i is a subcutaneously injectable ultra-long-acting amylin analog, with enhanced solubility and miscibility with its other NuSH analog peptides. MET-224o is an oral, fully biased ultra-long acting GLP-1 RA. The Company's pipeline also includes MET-002o, MET-AMYo, MET-034i, MET-067i and MET-PYYi.
Información de la empresa
Símbolo de cotizaciónMTSR
Nombre de la empresaMetsera Inc
Fecha de salida a bolsaJan 31, 2025
Director ejecutivoMr. Christopher Whitten Bernard
Número de empleados74
Tipo de seguridadOrdinary Share
Fin del año fiscalJan 31
Dirección3 World Trade Center
CiudadNEW YORK
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal10007
Teléfono12127846595
Sitio Webhttps://metsera.com/
Símbolo de cotizaciónMTSR
Fecha de salida a bolsaJan 31, 2025
Director ejecutivoMr. Christopher Whitten Bernard
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Paul L. Berns
Mr. Paul L. Berns
Independent Director
Independent Director
957.56K
--
Mr. Matthew Lang, J.D.
Mr. Matthew Lang, J.D.
Chief Legal Officer and Secretary
Chief Legal Officer and Secretary
--
--
Dr. Brian Hubbard, Ph.D.
Dr. Brian Hubbard, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Dr. Steven Marso, M.D.
Dr. Steven Marso, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Kristina M. Burow
Ms. Kristina M. Burow
Independent Director
Independent Director
--
--
Dr. Joshua Pinto, Ph.D.
Dr. Joshua Pinto, Ph.D.
Independent Director
Independent Director
--
--
Dr. Clive A. Meanwell, M.D.
Dr. Clive A. Meanwell, M.D.
Executive Chairman of the Board, Founder
Executive Chairman of the Board, Founder
--
--
Mr. Christopher Whitten Bernard
Mr. Christopher Whitten Bernard
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Christopher J. (Chris) Visioli
Mr. Christopher J. (Chris) Visioli
Chief Financial Officer, Chief Business Officer
Chief Financial Officer, Chief Business Officer
--
--
Mr. Jon P. Stonehouse
Mr. Jon P. Stonehouse
Independent Director
Independent Director
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Paul L. Berns
Mr. Paul L. Berns
Independent Director
Independent Director
957.56K
--
Mr. Matthew Lang, J.D.
Mr. Matthew Lang, J.D.
Chief Legal Officer and Secretary
Chief Legal Officer and Secretary
--
--
Dr. Brian Hubbard, Ph.D.
Dr. Brian Hubbard, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Dr. Steven Marso, M.D.
Dr. Steven Marso, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Kristina M. Burow
Ms. Kristina M. Burow
Independent Director
Independent Director
--
--
Dr. Joshua Pinto, Ph.D.
Dr. Joshua Pinto, Ph.D.
Independent Director
Independent Director
--
--
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: vie., 15 de ago
Actualizado: vie., 15 de ago
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
ARCH Venture Partners
25.53%
Fidelity Management & Research Company LLC
15.00%
Validae Health, L.P
12.15%
Alphabet, Inc.
4.72%
MIC Capital Management UK LLP
4.32%
Otro
38.28%
Accionistas
Accionistas
Proporción
ARCH Venture Partners
25.53%
Fidelity Management & Research Company LLC
15.00%
Validae Health, L.P
12.15%
Alphabet, Inc.
4.72%
MIC Capital Management UK LLP
4.32%
Otro
38.28%
Tipos de accionistas
Accionistas
Proporción
Venture Capital
36.77%
Investment Advisor
26.84%
Corporation
12.15%
Investment Advisor/Hedge Fund
9.96%
Hedge Fund
3.89%
Individual Investor
0.91%
Research Firm
0.12%
Bank and Trust
0.06%
Otro
9.30%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
133
95.51M
90.92%
+74.51M
2025Q1
104
95.08M
90.50%
+81.16M
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
ARCH Venture Partners
26.82M
25.53%
+26.82M
--
Feb 03, 2025
Fidelity Management & Research Company LLC
15.17M
14.44%
+4.11M
+37.16%
Mar 31, 2025
Validae Health, L.P
12.77M
12.15%
+12.77M
--
Mar 31, 2025
Alphabet, Inc.
4.96M
4.72%
+4.96M
--
Mar 31, 2025
MIC Capital Management UK LLP
4.54M
4.32%
+4.54M
--
Mar 31, 2025
VR Adviser, LLC
3.75M
3.57%
+3.75M
--
Mar 31, 2025
Wellington Management Company, LLP
2.40M
2.29%
+544.29K
+29.30%
Mar 31, 2025
Janus Henderson Investors
2.91M
2.77%
+2.91M
--
Mar 31, 2025
T. Rowe Price Investment Management, Inc.
2.89M
2.75%
+2.89M
--
Mar 31, 2025
Alpha Wave Global, LP
2.38M
2.27%
+2.38M
--
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: mié., 6 de ago
Actualizado: mié., 6 de ago
Nombre
Proporción
Roundhill GLP-1 & Weight Loss ETF
4.05%
ALPS Medical Breakthroughs ETF
2.02%
Virtus LifeSci Biotech Clinical Trials ETF
0.74%
SPDR S&P Biotech ETF
0.16%
Direxion Daily S&P Biotech Bull 3X Shares
0.1%
JPMorgan BetaBuilders US Small Cap Equity ETF
0.03%
Invesco Russell 2000 Dynamic Multifactor ETF
0.03%
ProShares Hedge Replication ETF
0.02%
Global X Russell 2000 ETF
0.02%
Proshares Ultra Russell 2000
0.02%
Ver más
Roundhill GLP-1 & Weight Loss ETF
Proporción4.05%
ALPS Medical Breakthroughs ETF
Proporción2.02%
Virtus LifeSci Biotech Clinical Trials ETF
Proporción0.74%
SPDR S&P Biotech ETF
Proporción0.16%
Direxion Daily S&P Biotech Bull 3X Shares
Proporción0.1%
JPMorgan BetaBuilders US Small Cap Equity ETF
Proporción0.03%
Invesco Russell 2000 Dynamic Multifactor ETF
Proporción0.03%
ProShares Hedge Replication ETF
Proporción0.02%
Global X Russell 2000 ETF
Proporción0.02%
Proshares Ultra Russell 2000
Proporción0.02%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
